Comparative Pharmacology
Head-to-head clinical analysis: ANGIOTENSIN LL ACETATE versus VASOSTRICT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOTENSIN LL ACETATE versus VASOSTRICT.
ANGIOTENSIN ll ACETATE vs VASOSTRICT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.
Vasopressin is a synthetic analogue of the antidiuretic hormone (ADH) that acts on V1 receptors (vascular smooth muscle) to cause vasoconstriction, and on V2 receptors (renal collecting ducts) to increase water reabsorption. At high doses used in vasodilatory shock, it primarily increases systemic vascular resistance via V1 receptor activation.
Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.
0.01-0.03 units/min IV continuous infusion, titrate to effect. Maximum 0.1 units/min.
None Documented
None Documented
Terminal elimination half-life is approximately 30-60 minutes; clinical effect is short-lived requiring continuous intravenous infusion.
Terminal elimination half-life is approximately 10–20 minutes, with clinical effect terminated rapidly by enzymatic degradation (catechol-O-methyltransferase and monoamine oxidase) in the liver and other tissues.
Primarily renal (90-100%) as unchanged drug; minimal biliary/fecal elimination (<10%).
Primarily renal (90–95% as inactive metabolites); minor biliary/fecal excretion (<5%).
Category C
Category C
Vasopressor
Vasopressor